Send us a text

Ian Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. Listen to this conversation to consider what "efficiency" means in the context of patient diagnosis and whether "less expensive" is always more efficient.

In this conversation, he questions whether positioning a second blood-based test between FIB-4 and FibroScan improves cost-effectiveness or, simple diagnosis. One Spoiler Alert: The Leeds data suggests that efficient screening processes for NAFLD and alcoholic liver disease may differ significantly. Stephen Harrison notes that polygenetic testing will introduce an entirely new set of issues to this question. There's a lot to consider here...